NanoViricides, Inc. (NYSE American: NNVC) announced it has submitted an application to the Democratic Republic of Congo's regulatory agency seeking approval to initiate a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the ongoing Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with drug supplies already positioned in the DRC.
NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells, an approach the company believes may reduce the likelihood of viral resistance. The planned study builds on NanoViricides' ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May.
The company said it believes NV-387's oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings. If successful, the treatment could support development of a broad-spectrum therapy for Ebola and other filoviruses. For more details, see the full press release at https://ibn.fm/tmrCX.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company is also developing drugs against a range of viral diseases including herpes, influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola.
The company's platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific mechanisms for human viral diseases such as HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.
As with any drug development, there can be no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
